CORT's Q4 Earnings and Revenues Fall Short of Estimates
Portfolio Pulse from
Corcept Therapeutics (CORT) reported weaker-than-expected earnings and revenues for Q4 2024, despite year-over-year sales growth driven by Korlym.
February 27, 2025 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Corcept Therapeutics reported Q4 2024 earnings and revenues that fell short of estimates. Despite this, Korlym sales showed year-over-year growth.
The shortfall in earnings and revenues is likely to negatively impact CORT's stock price in the short term. However, the growth in Korlym sales may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100